Pharma giants are bankrolling obesity awareness campaigns, raising thorny questions about what constitutes drug advertising.
Vehicles move past a billboard that was part of Eli Lilly's obesity awareness campaign in India.
Bhawika Chhabra / Reuters
Pharma giants are bankrolling obesity awareness campaigns globally. In an analysis, Swissinfo examines thorny questions about whether drug advertising bans are still enforceable – or even relevant.
Generated with artificial intelligence.
This content was published on
Pfizer made one thing clear this week: It's officially back in the obesity race.
Swiss pharmaceutical firm Roche is investing billions in new obesity treatments in hopes of breaking into a highly competitive…
Employers can use Lilly's platform to connect with different third-party program administrators that help manage obesity…
The rise of direct-to-consumer channels, driven largely by consumer willingness to pay for GLP-1s for weight loss without using…
CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare Conference…
Eli Lilly reported stellar third-quarter earnings yesterday and raised this year’s revenue estimates from $60 billion–$62 billion…
